These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 34183144)

  • 1. Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency.
    Butterfield RJ
    Semin Pediatr Neurol; 2021 Jul; 38():100899. PubMed ID: 34183144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening.
    Trollmann R; Johannsen J; Vill K; Köhler C; Hahn A; Illsinger S; Pechmann A; Hagen MV; Müller-Felber W
    Orphanet J Rare Dis; 2024 Sep; 19(1):353. PubMed ID: 39327607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinal Muscular Atrophy.
    Nicolau S; Waldrop MA; Connolly AM; Mendell JR
    Semin Pediatr Neurol; 2021 Apr; 37():100878. PubMed ID: 33892848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment.
    Nishio H; Niba ETE; Saito T; Okamoto K; Takeshima Y; Awano H
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
    McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
    Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
    Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
    Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.
    Lee BH; Waldrop MA; Connolly AM; Ciafaloni E
    Muscle Nerve; 2021 Aug; 64(2):153-155. PubMed ID: 33959970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era.
    Zettler B; Estrella E; Liaquat K; Lichten L
    J Genet Couns; 2022 Jun; 31(3):803-814. PubMed ID: 35037741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spinal muscular atrophy].
    Martin P; Horber V; Park J; Kronlage C; Grimm A
    Nervenarzt; 2022 Feb; 93(2):191-200. PubMed ID: 35037967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go.
    Dangouloff T; Vrščaj E; Servais L; Osredkar D;
    Neuromuscul Disord; 2021 Jun; 31(6):574-582. PubMed ID: 33985857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies.
    Angilletta I; Ferrante R; Giansante R; Lombardi L; Babore A; Dell'Elice A; Alessandrelli E; Notarangelo S; Ranaudo M; Palmarini C; De Laurenzi V; Stuppia L; Rossi C
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
    Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
    Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 16. Integrated Approaches and Practical Recommendations in Patient Care Identified with 5q Spinal Muscular Atrophy through Newborn Screening.
    Romanelli Tavares VL; Mendonça RH; Toledo MS; Hadachi SM; Grindler CM; Zanoteli E; Marques W; Oliveira ASB; Breinis P; Morita MDPA; França MC
    Genes (Basel); 2024 Jun; 15(7):. PubMed ID: 39062637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2024 update: European consensus statement on gene therapy for spinal muscular atrophy.
    Kirschner J; Bernert G; Butoianu N; De Waele L; Fattal-Valevski A; Haberlova J; Moreno T; Klein A; Kostera-Pruszczyk A; Mercuri E; Quijano-Roy S; Sejersen T; Tizzano EF; van der Pol WL; Wallace S; Zafeiriou D; Ziegler A; Muntoni F; Servais L
    Eur J Paediatr Neurol; 2024 Jul; 51():73-78. PubMed ID: 38878702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy.
    Chiang J; Xiao L; Nigro E; St-Laurent A; Weinstock L; Law E; Janevski J; Kuyntjes S; Cithiravel N; Tran T; Wolter NE; Gonorazky H; Amin R;
    Sleep Med; 2023 Nov; 111():161-169. PubMed ID: 37778092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1.
    Costamagna G; Govoni A; Wise A; Corti S
    Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.